.Pharmacolibrary.Drugs.ATC.A.A10AB05 .Pharmacolibrary.Drugs.ATC.A.A10AB05| name: | InsulinAspart |
| ATC code: | A10AB05 | route: | subcutaneous |
| n-compartments | 2 |
Insulin aspart is a fast-acting insulin analog used in the treatment of diabetes mellitus type 1 and type 2 to improve glycemic control. It is a recombinant human insulin with an amino acid substitution that allows for more rapid absorption after subcutaneous injection. It is approved and widely used in current clinical practice.
Pharmacokinetic parameters in healthy adult volunteers following single subcutaneous injection of insulin aspart.
Rasmussen, CH, et al., & Colding-Jørgensen, M (2014). Insulin aspart pharmacokinetics: an assessment of its variability and underlying mechanisms. European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences 62 65–75. DOI:10.1016/j.ejps.2014.05.010 PUBMED:https://pubmed.ncbi.nlm.nih.gov/24878388
Haahr, H, & Heise, T (2020). Fast-Acting Insulin Aspart: A Review of its Pharmacokinetic and Pharmacodynamic Properties and the Clinical Consequences. Clinical pharmacokinetics 59(2) 155–172. DOI:10.1007/s40262-019-00834-5 PUBMED:https://pubmed.ncbi.nlm.nih.gov/31667789
Liu, H, et al., & Yu, Y (2025). Evaluation of Pharmacokinetics and Safety of the Biosimilar (B01711) and Insulin Degludec/Insulin Aspart (IDegAsp, Ryzodeg) in Healthy Chinese Adults in a Randomized, Open-Label, Single-Dose, Crossover, Phase I Study. Drug design, development and therapy 19 2863–2871. DOI:10.2147/DDDT.S500347 PUBMED:https://pubmed.ncbi.nlm.nih.gov/40236299